伊班膦酸钠与唑来膦酸治疗前列腺癌骨转移的临床疗效分析  

Clinical efficacy of ibandronate and zoledronic acid in treatment of bone metastases of prostate cancer

作　　者：何清柳 张建育[1] 颜醒愚[1] HE Qingliu;ZHANG Jianyu;YAN Xingyu(Department of Urology,the Second Affiliated Hospital of Fujian Medical University,Quanzhou362000,China)

机构地区：[1]福建医科大学附属第二医院泌尿外科

出　　处：《中国现代医生》2019年第30期83-85,共3页China Modern Doctor

基　　金：福建省医学创新课题（2016-CX-37）

摘　　要：目的对比伊班膦酸钠与唑来膦酸治疗前列腺癌骨转移的有效性。方法回顾性分析2015年1月~2019年3月至我院治疗的48例前列腺癌骨转移患者,分为对照组(n=24,行伊班膦酸钠治疗)、观察组(n=24,行唑来膦酸治疗)。对两组患者治疗前和治疗3个疗程后疼痛控制效果、不良反应、夜间睡眠质量、血清碱性磷酸酶(Alkaline phosphatase,ALP)进行评估并比较。结果治疗前与治疗3个疗程后相比,两组的疼痛均明显控制,对照组和观察组疼痛控制率分别为87.5%、83.3%,两组之间差异无统计学意义(P>0.05);两组的不良反应发生率比较,差异无统计学意义(P>0.05);治疗3个疗程后,两组的夜间睡眠质量均明显改善(P<0.05),但两组之间差异无统计学意义(P>0.05);治疗3个疗程后,两组的ALP均明显下降(P<0.05),但两组之间差异无统计学意义(P>0.05)。结论伊班膦酸钠与唑来膦酸治疗前列腺癌骨转移患者,均有明显的临床疗效,能良好地控制疼痛,改善夜间睡眠,明显降低ALP,副作用小。Objective To compare the effectiveness of ibandronate and zoledronic acid in the treatment of bone metastases of prostate cancer. Methods Forty-eight patients with bone metastases of prostate cancer treated in our hospital from January 2015 to March 2019 were analyzed retrospectively and divided into the control group(n=24, treated with ibandronate) and the observation group(n=24, treated with zoledronic acid). The pain control effects, adverse reactions,nocturnal sleep quality and serum alkaline phosphatase(ALP) of the two groups were evaluated and compared before treatment and after 3 courses of treatment. Results After 3 courses of treatment, the pain was obviously controlled in both groups compared with that before treatment, and the pain control rate was 87.5% in the control group and 83.3%in the observation group, with no significant difference between the two groups(P>0.05);There was no significant dif ference in the incidence of adverse reactions between the two groups(P>0.05);After 3 courses of treatment, the nocturnal sleep quality was significantly improved in both groups(P<0.05), but the difference between the two groups was not statistically significant(P>0.05);After 3 courses of treatment, the ALP was significantly decreased in the two groups(P<0.05), but the difference between the two groups was not statistically significant(P>0.05). Conclusion Both ibandronate and zoledronic acid have significant clinical effects in the treatment of bone metastases of prostate cancer, can control pain well, improve nocturnal sleep quality and significantly reduce ALP, and have fewer side effects.

关 键 词：伊班膦酸钠 唑来膦酸 前列腺癌 骨转移 血清碱性磷酸酶 

分 类 号：R737.25[医药卫生—肿瘤]